Company: LIMN
Filing Date: 2025-06-24
Form Type: S-1
Source: 0001410578-25-001432
Chunk: 132

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-24
Form: S-1
Chunk 132
---
) at 100 mg/kg/ dose. Anti-drug antibody analysis, toxicokinetic parameters, organ weights, and macroscopic and microscopic examinations. |

On Day 22, the combined sex mean C0, Cmax, and AUC0-168hr values of IBA101 at the NOAEL were:

| ● | No C0 (Initial Plasma Concentration): 4,310,000 ng/mL |

| ● | Cmax (Maximum Plasma Concentration): 4,080,000 ng/mL |

| ● | AUC0-168hr (Area Under the Concetration-Time Curve): 359,000,000 hr*ng/mL. |

| ● | These toxicokinetic results suggest a good safety profile of IBA101 under the tested conditions and provide statistical evidence for its tolerability. |

Efficacy-related studies

| ● | CD47 antibody blocks interaction of CD47 and SIRPα |

| ● | A competitive ELISA assay demonstrated that the interaction between recombinant CD47 and recombinant SIRPα proteins was blocked by Hu3A5 in vitro. |

| ● | CD47 antibody promotes phagocytosis of live tumor cells by human macrophages. |

| ● | In vitro phagocytosis assay demonstrated that human macrophages promoted the uptake of live tumor cells in the presence of as low as > 0.1 micro grams/ml of CD47 mAb. |

| ● | Exclusive blockade of human CD47 on tumor cells with Hu3A5 in combination with check-point inhibitors induces a limited synergistic suppression of tumor growth. |

| ● | To assess how effectively CD47 blockade enhances anti-tumor responses, hCD47-expressing MC38 tumor cells were subcutaneously engrafted into normal C57BL/6 mice, and anti-human CD47 monoclonal antibodies were injected to specifically block the function of the hCD47 protein on tumor cells, allowing evaluation of the resulting increase in anti-tumor effects. |

| ● | This induced moderate delayed tumor growth. |

| ● | However, in combination with anti-PD-L1 and anti-TIGIT check-point inhibitors significant synergistic activity was observed where tumor growth was regressed and most of the mice became tumor-free. |

| ● | Global blockade of human CD47 on tumor and immune cells induces significant reduction of tumor growth. |

| ● | Investigated whether global effects of CD47 blockade would be beneficial if all cells including immune cells were expressing